AliveCor's KardiaMobile® 6L Becomes First Personal ECG Device Recommended for Use in Psychiatric Services in England and Wales
Mountain View, CA, USA, September 26, 2023
Mountain View, CA, USA, September 26, 2023
AliveCor, the world’s leading innovator in personal electrocardiogram (ECG) technology, today announced the publication of the Early Value Assessment (EVA) by the National Institute for Health and Care Excellence (NICE) which conditionally recommends the use of KardiaMobile 6L in psychiatric services as an option to measure cardiac QT interval for adults having, or about to have, antipsychotic medication.1
There is an unmet clinical need for a more easily accessible and available measurement for detecting cardiac abnormalities in NHS psychiatric services, as antipsychotic medication can prolong the QT interval* and lead to severe cardiac events.1 Detecting cardiac abnormalities in people taking antipsychotic medication – such as prolonged QT interval – can inform choice of therapy, dosing and whether to stop therapy, and potentially avoid severe cardiac events, which are contributing to the significantly lower life expectancy of these patients, as compared to the general population.1,2 KardiaMobile 6L is a portable ECG recording device that provides instant detection of cardiac abnormalities and can be used to measure heart changes including cardiac QT interval.1
“Timely ECG monitoring of patients who are on antipsychotic medication can save lives. Having access to KardiaMobile 6L will mean potentially vulnerable patients can now be seen in the comfort of their homes, reducing their stress whilst ensuring that this essential monitoring is completed anywhere, at any time. It’s encouraging that NICE has recognised the need for early access to this important technology” said Dr Mani Krishnan, Consultant Psychiatrist and Specialty Clinical Director Tees, Esk and Wear Valleys NHS Foundation Trust.
KardiaMobile 6L has been recommended as part of NICE’s EVA pilot project, created to drive earlier access to promising healthcare innovations for use within the National Health Service in England and Wales. The first and only NICE recommended smartphone-based ECG device, KardiaMobile 6L can be used by healthcare professionals in both a hospital setting and as part of routine home visits.1 This may reduce stress and anxiety amongst psychiatric patients as the test can be completed in familiar surroundings.1 Portable ECG testing also eliminates the need for travel and the requirement for conductive gel and undressing, which can cause reluctance and distress for patients.1 KardiaMobile 6L has the potential to ensure timely ECG testing is available which could help adults having antipsychotic medication get faster access to safe and effective antipsychotic treatment.1
“We are delighted that KardiaMobile 6L has been recognised by NICE and reviewed by the Early Value Assessment pilot project. This decision is testament to the clinical importance of detecting and monitoring heart disturbances both in clinic and at home, something especially important in psychiatric services,” said Sean Warren, Business Director UK&I, AliveCor. “We have a wealth of clinical data on the use of KardiaMobile 6L in cardiology, with NICE’s EVA recommendation we will now support the collection of real-world evidence as to its effectiveness in psychiatric services. We applaud NICE and the physicians that have worked on this project for their forward-thinking approach to the use of novel health tech within the NHS, as we know it is patients that will be the ultimate beneficiaries.”
NICE’s decision was based on a systematic review of eight studies that evaluated the technical performance of KardiaMobile 6L compared with a 12-lead device.1 Conditional to NICE’s positive recommendation is that further evidence on the use of this innovative technology in psychiatric services must be generated to inform a further full technology reassessment.1
*A prolonged QT interval indicates an abnormality detected on an ECG. This abnormality reflects a disturbance in the conduction of electricity in the lower chamber (ventricles) of the heart.3 Multiple factors can trigger prolonged QT interval including high doses of medications such as antihistamines, decongestants, diuretics, antibiotics, and antidepressants.3
AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile device is the most clinically-validated personal ECG solution in the world. KardiaMobile 6L provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular Contractions, Sinus Rhythm with Wide QRS, and Normal Sinus Rhythm in an ECG. Kardia is the first AI-enabled platform to aid patients and clinicians in the efficient detection of atrial fibrillation, the most common arrhythmia and one associated with a highly-elevated risk of stroke. AliveCor's enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies. AliveCor protects its customers with stringent data security and compliance practices, achieving ISO 27001 Certification, SOC 2 Type 2 Certification and HIPAA compliance attestation. AliveCor is a privately-held company headquartered in Mountain View, Calif. “Consumer” or “Personal” ECGs are ECG devices available for direct sale to consumers. For more information, visit alivecor.com.
1 NICE. Health Technology Evaluation: KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication (HTE10). 2023. Available at: https://www.nice.org.uk/guidan.... Last accessed: September 2023.
2 NICE. Diagnostics Assessment Programme: KardiaMobile 6L for measuring QT interval in people having antipsychotic medication. Final scope. 2022. Available at: https://www.nice.org.uk/guidan.... Last accessed: September 2023.
3 NHS Long QT Syndrome. 2017. Available at: https://www.nhs.uk/conditions/.... Last accessed: September 2023.
November 10, 2023
September 27, 2023
July 26, 2023
Let's transform cardiovascular care together
If you are an employer or payer looking for a comprehensive heart health enterprise solution, contact us.